Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Director · President and CEO | September 08, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protagonist Therapeutics, Inc
Report date September 08, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 522,968 |
Ending reported balance
After 2026-09-10 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-09-08 · Exercise / conversion · Acquired 54,174 · Balance 577,142 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Row 2 · 2026-09-08 · Sale · Disposed 54,174 · Balance 522,968 F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.00 to $147.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Row 3 · 2026-09-09 · Exercise / conversion · Acquired 63,548 · Balance 586,516 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Row 4 · 2026-09-09 · Sale · Disposed 63,548 · Balance 522,968 F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $144.49 to $151.27. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Row 5 · 2026-09-10 · Exercise / conversion · Acquired 7,278 · Balance 530,246 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. Row 6 · 2026-09-10 · Sale · Disposed 7,278 · Balance 522,968 F4: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.51 to $145.19. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.58 · Expires 2026-10-11 | Direct | 70,826 |
Reported balance
After 2026-09-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-08 · Exercise / conversion · Disposed 54,174 · Balance 70,826 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.58 · Expires 2026-10-11 | Direct | 7,278 |
Reported balance
After 2026-09-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-09 · Exercise / conversion · Disposed 63,548 · Balance 7,278 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.58 · Expires 2026-10-11 | Direct | 0 |
Reported balance
After 2026-09-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-10 · Exercise / conversion · Disposed 7,278 · Balance 0 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options.
F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.00 to $147.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $144.49 to $151.27. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.51 to $145.19. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 22, 2025 Filed Jul 23, 2025 22:57 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 22,065 | $55.05 | $1,214,678.25 |
DisclosureSEC source: 0001104659-25-070104 · tm2521572-1_4seq1.xml · nonDerivative · entry 3 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 548,538 F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.00 to $55.19. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 21, 2025 Filed Jul 23, 2025 22:57 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 12,859 | $54.86 | $705,444.74 |
DisclosureSEC source: 0001104659-25-070104 · tm2521572-1_4seq1.xml · nonDerivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 570,603 F2 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of PSUs. Read SEC document |
| July 21, 2025 Filed Jul 23, 2025 22:57 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-070104 · tm2521572-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 583,462 F1 · shares: Represents settlement by the Issuer of performance stock units ("PSUs") granted to the Reporting Person under the Issuer's 2016 Equity Incentive Plan on February 26, 2021, which vested based on the Issuer's achievement of corporate performance objectives. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:01 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-069011 · tm2521210-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 558,462 F1 · kind: On July 16, 2025, the Reporting Person made a charitable donation of 5,000 shares of common stock to a donor-advised fund, which will use the gifted shares for charitable purposes. F2 · balance_after: Includes an aggregate of 557 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 7, 2025. Read SEC document |
| June 16, 2025 Filed Jun 17, 2025 20:01 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GiftCommon Stock | 685 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-060239 · tm2518201-1_4seq1.xml · nonDerivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 562,905 F1 · kind: This transaction involves a bona fide gift of securities from the Reporting Person to his grandchildren. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 20:01 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GiftCommon Stock | 670 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-060239 · tm2518201-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 563,590 F1 · kind: This transaction involves a bona fide gift of securities from the Reporting Person to his grandchildren. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 01:02 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001104659-25-021045 · tm258430-1_4seq1.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 24,000 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 01:02 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 24,000 | $4.21 | $101,040.00 |
DisclosureSEC source: 0001104659-25-021045 · tm258430-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 564,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 22:25 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 5,359 | $38.18 | $204,606.62 |
DisclosureSEC source: 0001104659-25-015734 · tm257231-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 540,260 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 22:46 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Tax withholdingCommon Stock | 12,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004570 · tm253633-2_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 545,619 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:07 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 181,472 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001104659-25-001429 · tm252003-4_4seq1.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,472 Underlying: Common Stock · 181,472 shares Expires 2035-01-02 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:07 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 149,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-001429 · tm252003-4_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 558,255 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in four equal annual installments on January 15, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:08 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 21,480 | $46.25 | $993,450.00 |
DisclosureSEC source: 0001104659-24-123806 · tm2429758-1_4seq1.xml · nonDerivative · entry 4 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 408,455 F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $44.49 to $46.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2024 Filed Nov 28, 2024 00:08 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 1,727 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001104659-24-123806 · tm2429758-1_4seq1.xml · derivative · entry 5 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,273 Underlying: Common Stock · 1,727 shares Expires 2026-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| November 25, 2024 Filed Nov 28, 2024 00:08 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 1,727 | $21.58 | $37,268.66 |
DisclosureSEC source: 0001104659-24-123806 · tm2429758-1_4seq1.xml · nonDerivative · entry 3 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 429,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2024 Filed Nov 28, 2024 00:08 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GiftCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-123806 · tm2429758-1_4seq1.xml · nonDerivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,208 F3 · kind: On November 25, 2024, the Reporting Person made a charitable donation of 7,000 shares of common stock to a donor-advised fund, which will use the gifted shares for charitable purposes. Read SEC document |
| November 25, 2024 Filed Nov 28, 2024 00:08 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 78,520 | $46.96 | $3,687,299.20 |
DisclosureSEC source: 0001104659-24-123806 · tm2429758-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 435,208 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $46.50 to $47.47. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes an aggregate of 313 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2024. Read SEC document |
| November 19, 2024 Filed Nov 21, 2024 21:01 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-121501 · tm2429110-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 513,415 F1 · kind: This transaction involves a bona fide gift of securities from the Reporting Person to his grandchild. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:30 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-072307 · tm2417453-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 514,415 F1 · kind: This transaction involves a bona fide gift of securities from the Reporting Person to his grandchild. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:30 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 35,000 | $35.19 | $1,231,650.00 |
DisclosureSEC source: 0001104659-24-070419 · tm2416932-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 515,415 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2023. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $35.00 to $35.53. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes an aggregate of 825 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2024. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 00:29 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 25,000 | $28.31 | $707,750.00 |
DisclosureSEC source: 0001104659-24-042744 · tm2410626-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 549,590 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2023. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $27.69 to $28.77. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 01:46 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 30,000 | $31.62 | $948,600.00 |
DisclosureSEC source: 0001104659-24-030159 · tm247765-3_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 574,590 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2023. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $30.28 to $32.25. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 01:02 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Tax withholdingCommon Stock | 10,915 | $29.53 | $322,319.95 |
DisclosureSEC source: 0001104659-24-028888 · tm247552-2_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 604,590 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 25,000 restricted stock units on February 26, 2024. Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:00 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Tax withholdingCommon Stock | 3,717 | $28.23 | $104,930.91 |
DisclosureSEC source: 0001104659-24-025685 · tm246687-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 615,505 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 10,417 restricted stock units on February 15, 2024. Read SEC document |
| January 02, 2024 Filed Jan 5, 2024 01:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 315,250 | $0.00 Strike: $23.42 | $0.00 |
DisclosureSEC source: 0001104659-24-001492 · tm241954-4_4seq1.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 315,250 Underlying: Common Stock · 315,250 shares Expires 2034-01-02 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2024 Filed Jan 5, 2024 01:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 84,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-001492 · tm241954-4_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 619,222 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in three equal annual installments on January 15, 2025, 2026 and 2027, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 21:30 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 75,000 | $20.08 | $1,506,000.00 |
DisclosureSEC source: 0001104659-23-126419 · tm2333032-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 534,347 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2023. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.20. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2023 Filed Oct 19, 2023 20:55 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001104659-23-110157 · tm2328807-1_4seq1.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 6,000 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| October 18, 2023 Filed Oct 19, 2023 20:55 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 6,000 | $4.21 | $25,260.00 |
DisclosureSEC source: 0001104659-23-110157 · tm2328807-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 609,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 401 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2023. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:50 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Tax withholdingCommon Stock | 12,165 | $26.07 | $317,141.55 |
DisclosureSEC source: 0001104659-23-067690 · tm2317724-2_4seq1.xml · nonDerivative · entry 3 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602,946 F4 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of PSUs. F1 · balance_after: The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the "Lock-up Date") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:50 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-067690 · tm2317724-2_4seq1.xml · nonDerivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 615,111 F2 · shares: Represents settlement by the Issuer of performance stock units ("PSUs") granted to the Reporting Person under the Company's 2016 Equity Incentive Plan on May 31, 2022, which vested based on the Issuer's achievement of corporate performance objectives. F1 · balance_after: The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the "Lock-up Date") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date. F3 · balance_after: Includes an aggregate of 1,663 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2023. Read SEC document |
| February 22, 2023 Filed Jun 2, 2023 23:50 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-067690 · tm2317724-2_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 583,448 F1 · balance_after: The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the "Lock-up Date") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date. Read SEC document |
| January 16, 2023 Filed Jan 19, 2023 00:48 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-23-004721 · tm233829-7_4.xml · derivative · entry 3 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2033-01-15 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| December 28, 2022 Filed Jan 19, 2023 00:48 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GiftCommon Stock | 3,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004721 · tm233829-7_4.xml · nonDerivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 598,096 F1 · balance_after: Includes an aggregate of 164 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2022. Read SEC document |
| August 23, 2022 Filed Aug 24, 2022 22:15 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0000899243-22-029621 · doc4.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 20,000 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is vested in full. Read SEC document |
| August 23, 2022 Filed Aug 24, 2022 22:15 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 20,000 | $4.21 | $84,200.00 |
DisclosureSEC source: 0000899243-22-029621 · doc4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 604,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2022 Filed May 5, 2022 00:33 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 15,742 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001104659-22-055995 · tm2214526-2_4seq1.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 15,742 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is vested in full. Read SEC document |
| May 04, 2022 Filed May 5, 2022 00:33 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 15,742 | $4.21 | $66,273.82 |
DisclosureSEC source: 0001104659-22-055995 · tm2214526-2_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2022 Filed Jan 19, 2023 00:48 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004721 · tm233829-7_4.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 581,048 Read SEC document |
| April 26, 2022 Filed Apr 27, 2022 01:34 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001104659-22-050551 · tm2212815-4_4seq1.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,742 Underlying: Common Stock · 30,000 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is vested in full. Read SEC document |
| April 26, 2022 Filed Apr 27, 2022 01:34 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 30,000 | $4.21 | $126,300.00 |
DisclosureSEC source: 0001104659-22-050551 · tm2212815-4_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 459 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2022. Read SEC document |
| April 14, 2022 Filed Apr 15, 2022 00:09 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 34,087 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001104659-22-046158 · tm2212815-1_4seq1.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,087 shares Expires 2024-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is vested in full. Read SEC document |
| April 14, 2022 Filed Apr 15, 2022 00:09 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 34,087 | $1.89 | $64,424.43 |
DisclosureSEC source: 0001104659-22-046158 · tm2212815-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 01:39 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Tax withholdingCommon Stock | 4,648 | $24.28 | $112,853.44 |
DisclosureSEC source: 0001104659-22-029520 · tm228264-2_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,760 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of 13,438 vested restricted stock units on February 28, 2022. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 00:23 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 187,500 | $0.00 Strike: $28.73 | $0.00 |
DisclosureSEC source: 0001104659-22-024835 · tm227111-1_4seq1.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2032-02-14 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 00:23 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-024835 · tm227111-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 508,408 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on February 15, 2023, 2024 and 2025. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 21:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 15,000 | $32.14 | $482,170.50 |
DisclosureSEC source: 0001104659-21-153135 · tm2136222-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477,158 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.86 to $32.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 01:45 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001104659-21-118054 · tm2128192-1_4seq1.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,742 Underlying: Common Stock · 40,000 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is vested in full. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 01:45 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 40,000 | $4.21 | $168,400.00 |
DisclosureSEC source: 0001104659-21-118054 · tm2128192-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 1,014 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021 and September 9, 2021. Read SEC document |
| February 26, 2021 Filed Feb 26, 2021 23:33 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $23.57 | $0.00 |
DisclosureSEC source: 0001209191-21-014981 · doc4.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2031-02-25 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.